IMMUNOGENIC AGENT THERAPY USING PLASMAPHERESIS
Lowering the level of antibody or complement in the blood of a subject by plasmapheresis or exchange transfusion prior to administering an immunogenic therapeutic agent containing a foreign epitope reduces the immune response of the subject to the therapeutic agent.
1 . A method of reducing the immune response to an immunogenic therapeutic agent in a subject to whom the agent is administered wherein the agent contains at least one epitope foreign to the subject, comprising treating the subject with plasmapheresis to lower the level of antibody or complement in blood of the subject prior to administering the agent;
wherein the plasmapheresis comprises:
(i) (a) obtaining from the subject blood which comprises cells and plasma, which plasma comprises antibodies or complement; (b) centrifuging the blood or filtering the blood with a filter, to isolate the plasma from the cells; and (c) returning the cells and not the plasma to the subject;
or
(ii) (a) obtaining from the subject blood which comprises cells and plasma, which plasma comprises antibodies or complement; (b) filtering the blood with a first filter to separate the plasma from the cells;
(c) returning the cells to the subject; (d) size-filtering the plasma isolated in step (b) with a second filter to deplete antibody or complement from the plasma; and (e) returning the depleted plasma to the subject.
2 . The method of claim 1 , wherein the agent is a therapeutic virus.
3 . The method of claim 2 , wherein the virus is an oncolytic virus.
4 . The method of claim 3 , wherein the oncolytic virus is a Newcastle Disease Virus.
5 . The method of claim 3 , wherein the oncolytic virus is a Vesicular Stomatitis Virus.
6 . The method of claim 3 , wherein the oncolytic virus is a reovirus.
7 . The method of claim 2 , wherein the virus is an adenovirus or a herpes virus.
8 . The method of claim 1 , wherein the agent is bacterial.
9 . The method of claim 8 , wherein the bacterial therapeutic agent is a Salmonella.
10 . The method of claim 9 , wherein the agent is a Salmonella typhimurium.
11 . The method of claim 8 , wherein the bacterial therapeutic agent is a Clostridium.
12 . The method of claim 8 , wherein the bacterial therapeutic agent is a Bifidobacterium.
13 . The method of claim 1 , wherein the plasmapheresis is performed up to twenty-four hours before administration of the agent.
14 . The method of claim 13 , wherein the plasmapheresis is performed up to six hours before administration of the agent.
15 . The method of claim 14 , wherein the plasmapheresis is performed up to one hour before administration of the agent.
16 . The method of claim 1 , wherein the plasmapheresis comprises: (a) obtaining from the subject blood which comprises cells and plasma, which plasma comprises antibodies or complement; (b) centrifuging the blood to isolate the plasma from the cells; and (c) returning the cells and not the plasma to the subject.
17 . The method of claim 1 , wherein the plasmapheresis comprises: (a) obtaining from the subject blood which comprises cells and plasma, which plasma comprises antibodies or complement; (b) filtering the blood with a filter to separate the plasma from the cells; and (c) returning the cells and not the plasma to the subject.
18 . The method of claim 17 , wherein the filter has a size cut-off of from 0.1 to 0.6 microns.
19 . The method of claim 16 or 17 , further comprising infusing into the bloodstream of the subject a plasma-replacement fluid in an amount approximately equivalent in volume to the plasma resulting from step (b), wherein the plasma-replacement fluid is not the plasma resulting from step (b) and the infusion is performed after any one or more of steps (a), (b) or (c).
20 . The method of claim 19 , wherein the plasma-replacement fluid is plasma from a source other than the subject.
21 . The method of claim 1 , wherein the plasmapheresis comprises: (a) obtaining from the subject blood which comprises cells and plasma, which plasma comprises antibodies or complement; (b) filtering the blood with a first filter to separate the plasma from the cells; (c) returning the cells to the subject; (d) size-filtering the plasma isolated in step (b) with a second filter to deplete antibody or complement from the plasma; and (e) returning the depleted plasma to the subject.
22 . The method of claim 21 , wherein the first filter has a size cut-off of from 0.1 to 0.6 microns.
23 . The method of claim 21 , wherein the second filter has a molecular weight cut-off of from 60 to 150 kilodaltons.
24 . The method of claim 1 , wherein the subject is a human.
25 . The method of claim 1 , wherein the subject is a non-human mammal.